While some jurisdictions have limited the use of the Oxford University / AstraZeneca COVID-19 vaccine, the WHO says it can be used even where variants are known to be in circulation and with people aged 65+.
AstraZeneca and IDT Biologika are exploring options to accelerate output of finished COVID-19 Vaccine AstraZeneca in the second quarter of 2021 in order to help support Europe’s immediate vaccination needs during the pandemic.
Collaboration is not an unknown in the domain of pharmaceutical development, but it is rare enough. The demands of the COVID-19 pandemic, however, have seen competitors switch to become manufacturing allies.
Three COVID-19 vaccine manufacturing sites are set to start production in France in the coming weeks: while the French government is seeking to boost further production with a €300m ($363m) initiative announced on Monday.
UK catalyst organization, CPI, has announced the launch of a project that aims to revolutionize the manufacture of oligonucleotides, through a collaboration involving, among others, AstraZeneca, Exactmer, and Novartis.
Health officials in Azerbaijan have granted approval for a clinical trial to take place in that country combining Russia’s Sputnik V vaccine with the Oxford-AstraZeneca COVID-19 shot in adults 18 years and older.